COVID-19 Update: All AMP Locations are open, see how we are offering safe in person care and virtual visits. Click here to Learn more about Virtual Care Options.

Click here for additional COVID-19 Information

Non-Discrimination Notice

Merck 991

Merck 991 - Protocol Title: A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475)Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone 
Population:
Patients with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer
(mCRPC) 

Sponsored by: Merck
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 3